Navigation Links
Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
Date:10/22/2008

rldwide Pharmaceuticals net revenue increased 5% for the 2008 third quarter and first nine months due primarily to higher sales of Enbrel, Prevnar and Nutritional products, as well as the favorable impact of foreign exchange. Net revenue from Effexor and Zosyn also increased for the first nine months of 2008. Also contributing to net revenue growth were new products such as TYGACIL(R), TORISEL and PRISTIQ. The increase in Pharmaceuticals net revenue was offset, in part, by lower sales of the Protonix family. Excluding the favorable impact of foreign exchange, worldwide Pharmaceuticals net revenue increased 3% for the 2008 third quarter and increased 1% for the 2008 first nine months.

Consumer Healthcare

Worldwide Consumer Healthcare net revenue decreased 5% for the third quarter of 2008 due primarily to a decrease in sales of ROBITUSSIN(R) and ADVIL(R), partially offset by an increase in sales of CENTRUM(R) and the favorable impact of foreign exchange. Worldwide Consumer Healthcare net revenue increased 4% for the first nine months of 2008 due primarily to an increase in sales of Centrum and CALTRATE(R) and the favorable impact of foreign exchange, partially offset by lower sales of Robitussin. Excluding the favorable impact of foreign exchange, worldwide Consumer Healthcare net revenue decreased 6% for the 2008 third quarter and for the 2008 first nine months was comparable to the 2007 first nine months.

In September 2008, Consumer Healthcare completed the purchase of the THERMACARE(R) product line, a leading over-the-counter heat wrap, from Procter & Gamble. The transaction is expected to enhance Wyeth's global position in pain management.

Animal Health

Worldwide Animal Health net revenue increased 11% for the third quarter of 2008 due primarily to higher sales of livestock products, driven by ZULVAC(R) bluetongue vaccine, equine products and the favorable impact of foreign exchange. For the 2008 first nine months, net revenue in
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
2. Wyeth Announces Increase in Common Stock Dividend
3. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
4. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
5. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
6. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
7. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
8. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
9. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
10. Wyeth Declares Common and Preferred Stock Dividends
11. Wyeth Pharmaceuticals Announces Organizational Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015 The Dohmen Company ... , Ph.D., MBA as Chief Science Officer (CSO) ... newly created role, Dr. Floyd will lead Dohmen,s ... portfolio of pre-commercial and post approval outsourced services ... medical communications.  Dr. Floyd brings decades of experience ...
(Date:9/1/2015)... Sept. 1, 2015   Medfusion, Inc., ... relationship between doctors and patients, today announced a ... N.C. -based venture capital firms.   ... association with Bull City Venture Partners and Hatteras ... Founder and Executive Chairman. "Both firms, experience working ...
(Date:9/1/2015)... CA (PRWEB) , ... September 01, 2015 , ... ... and colleagues from University of California Los Angeles, Boston University School of Medicine, ... Prevention appears in PLOS One, the world’s first multidisciplinary Open Access journal. ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply Chain Resiliency ... and resiliency practitioners with luminaries and thought leaders to advance the professional discipline ... their innovations and performance excellence. At that time its principle sponsor, Resilinc ...
Breaking Biology Technology:Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3
... Brain Metastases, PALO ALTO, Calif., Sept. 2 ... radiosurgery treatments for,multiple brain metastases using new RapidArc ... ). The MIMA Cancer Center in Melbourne,Florida and ... able to treat brain metastases more quickly and ...
... BMRN ) today announced that Jean-Jacques,Bienaime, Chief Executive ... 3rd Annual Citi Biotech Day in New York City ... Interested parties may access a live audio webcast of ... website, http://www.BMRN.com .,A replay of the call will ...
... development milestone payment to InterMune - ... to lead ITMN-191 program in Phase 2 -, BRISBANE, ... announced that InterMune has earned a $15 million,development milestone under ... NS3 protease inhibitor compound ITMN-191,(referred to as R7227 at Roche), ...
Cached Biology Technology:Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 4BioMarin to Present at the Citi Biotech Day 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Hole Research Center are analyzing the surprising results of the ... rainforest. , From January 2000 to July 2004, rainfall was ... of the Tapajós National Forest, in Brazil. A total of ... by 6' clear plastic panels suspended 3 to 12 feet ...
... Affymetrix Inc. (Nasdaq: AFFX - News) and Karolinska ... a strategic alliance designed to improve healthcare by ... tools for better diagnosis, prognosis, and treatment. , ... genetic analyses and measurement of gene expression in ...
... have discovered an important chemical in the brain's ... symptoms of opioid drugs like morphine and heroin. ... chemical--called a transporter--could relieve some of the early ... shaking, and jumpiness. Such drugs could become part ...
Cached Biology News:World's largest rainforest drying experiment completes first phase 2World's largest rainforest drying experiment completes first phase 3Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3Key Trigger Of Opioid Withdrawal Symptoms Found 2